Weimin Liao

Weimin Liao

Auto-generated profile, based on publicly available information

Weimin Liao

Department of Emergency, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2020 in Biomarkers
Verified
Journal Article
Closed access
ZHZiyi Hu
Ziyi Hu
JLJunyu Lai
Junyu Lai
LCLisha Chen
Lisha Chen
YYYing Yi
Ying Yi
RLRenliang Li
Renliang Li
WLWeimin Liao
Weimin Liao
Background: The association between elevated C-reactive protein (CRP) level and poor functional outcome is conflicting in acute ischemic stroke (AIS) patients. This meta-analysis sought to investigate the value of elevated CRP level in predicting poor functional outcome in AIS patients. Materials and methods: A systematically literature search was performed in PubMed and Embase databases up to October 31, 2019. Prospective and retrospective studies evaluating the association between elevated CRP level and poor functional outcome (defined by the Modified Rankin Scale ≥3) beyond 3 months after AIS were included. Results: Ten studies with a total of 8087 AIS patients were identified in this meta-analysis. When compared with reference low CRP level, the highest CRP level was associated with an increased risk of poor functional outcome (multivariate-adjusted hazard ratio [HR] 1.99; 95% confidence interval [CI] 1.63–2.44) in a random effect model. Sensitivity analysis further confirmed the significance of CRP elevation for predicting poor functional outcome after AIS. Conclusions: Elevated CRP level is significantly associated with poor functional outcome in patients with AIS. Baseline CRP level has potential to improve risk stratification of function outcome in AIS patients.

1 July 2019 in Medicine
Verified
Journal Article
Open access
ZXZhongbo Xu
Zhongbo Xu
XFXin Feng
Xin Feng
LLLin Li
Lin Li
ZHZiyi Hu
Ziyi Hu
YXYuan Xiao
Yuan Xiao
WLWeimin Liao
Weimin Liao
Background: Chronic cerebral circulation insufficiency (CCCI) is a common clinical cerebrovascular disease, especially among middle-aged and elderly patients, which seriously endangers their quality of life and physical and mental health. At present, Oral traditional Chinese patent medicine (OTCPM) is widely used in the treatment of CCCI in China, but its actual efficacy and safety lack of evidence-based evidence. Therefore, we will screen out the most effective OTCPM through a systematic review and network meta-analysis to provide a reliable theoretical basis for clinical decisions. Methods: We will search electronic databases to collect relevant RCT studies from inception to October 2019. Those electronic databases include PubMed, Cochrane Library, Web of Science, EMBASE, China Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP), and Wan-fang database. Only randomized clinical trials (RCTs) concerned any OTCPM treatments for CCCI will be collected. The included studies will no restrictions on language or publication year. There were no publication year or language for the included literature. Risk bias tools will assess the quality of the included literature. A Bayesian NMA will be performed to combine the direct and indirect comparisons of TCPMs interventions. The surface under the cumulative ranking curve (SUCRA) will be drawn to display the hierarchy of each TCPMs treatment. All statistical analyses will be implemented using R v3.5.2. and GeMTC v1.4.3. We will publish this systematic review in academic journals. Since this literature review will not involve directly contacting patients, ethical approval and informed consent are not required. Trial registration number: CRD42019123878.